Suchergebnisse - "Labbate, Craig"

PubPharm (6)

1

First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors

enthalten in: Urologic oncology | 2024

von Jacob, J. | Woldu, S. | Linehan, J. | +18

2

The ablative effect of mitomycin reverse thermal gel : Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma

enthalten in: Urologic oncology | 2023

von Kaimakliotis, H. | Tachibana, I. | Woldu, S. | +17

3

Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes

enthalten in: Urologic oncology | 2023

von Woldu, S. | Labbate, C. | Murray, K. | +17

4

Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma

enthalten in: Urologic oncology | 2022

von Labbate, C. | Hensley, P. | Miest, T. | +14

5

The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer : A multi-institution analysis

enthalten in: Urologic oncology | 2021

von Packiam, V. | Labbate, C. | Boorjian, S. | +13

CommentIn: Nat Rev Urol. 2021 Jun;18(6):323-324. - PMID 33772157

6

National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy

enthalten in: Urologic oncology | 2020

von Labbate, C. | Werntz, R. | Galansky, L. | +2

1
[1]